PatientID: HDR99

Okitobba 06, 2023

Color Code

HR: High-Level Resistance

LR: Low-Level Resistance

IR: Intermediate Resistance

S: Susceptible

DRUG.CLASS	DRUG	RESISTANCE.PROFILE	DRMS.above.20.percent.prevalence
PI	ATV	S	
	DRV	${f S}$	
	FPV	${f S}$	
	IDV	${f S}$	
	LPV	${f S}$	
	NFV	${f S}$	
	SQV	${f S}$	
	TPV	${f S}$	
NRTI	ABC	${f S}$	
	AZT	PLR	
	D4T	PLR	
	DDI	${f S}$	K219E
	FTC	${f S}$	
	LMV	${f S}$	
	TDF	${f S}$	
NNRTI	DOR	PLR	
	EFV	$_{ m HR}$	
	ETR	PLR	L100V;K103N
	NVP	$_{ m HR}$	
	RPV	LR	

Appendix

Drug abbreviations in full

DRUG.CLASS	ABBREVIATION	DRUG.NAME
	ATV	Atazanavir
	DRV	Darunavir
	FPV	Fosamprenavir
PI	IDV	Indinavir
11	LPV	Lopinavir
	NFV	Nelfinavir
	SQV	Saquinavir
	TPV	Tipranavir
	ABC	Abacavir
	AZT	Azidothymidine
	DFT	Stavudine
NRTI	DDI	Didanosine
	FTC	Emtricitabine
	LMV	Lamivudine
	TDF	Tenofovir
	DOR	Doravirine
	EFV	Efavirenz
NNRTI	ETR	Etravirine
	NVP	Nevirapine
	RPV	Rilpivirine
	BIC	Bictegravir
	CAB	Cabotegravir
INSTI	DTG	Dolutegravir
	EVG	Elvitegravir
	RAL	Raltegravir

Comments

DRUG.CLASS	COMMENTS
PI	
NRTI	K219E/Q/N/R are accessory TAMS that usually occur in combination with multiple other
	TAMs.
NNRTI	K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EFV
	susceptibility. It is the most commonly transmitted DRM.
	L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In
	this setting it confers high-level resistance to NVP, EFV, and RPV and intermediate
	resistance to ETR and DOR. L100V is a rare mutations that likely has effects similar to
	L100I.
INSTI	